Report Detail

Other Anti-Diabetic Pharmaceuticals Market in India 2012

  • RnM2777937
  • |
  • 24 June, 2019
  • |
  • Global
  • |
  • 76 Pages
  • |
  • Netscribes
  • |
  • Other

Anti-diabetic pharmaceuticals market in India is one of the most lucrative diabetes markets in the world. Since India is the second largest diabetic pool in the world after China, the Indian market is characterized by a huge demand for anti-diabetic drugs. It is a highly fragmented market with a large number of foreign and domestic players. The huge increase in the number of diabetes cases, introduction of newer and better drugs, increasing aging population and introduction of diabetes insurance policies is helping the market to grow. The Indian Government, on its part, has introduced some diabetes control programmes. The market is expected to exhibit steady growth over the next few years.

The report begins with the introduction section which offers a brief classification of the different types of diabetes. It then gives a classification of the diabetes market, and then provides a brief description of different classes of anti-diabetic pharmaceuticals. The market overview section provides an insight into the global market and then moves on to the Indian market, highlighting the market size and growth. It also provides a global diabetes map.

An analysis of the drivers explains the factors for growth of the industry including increasing diabetes cases, introduction of newer and better drugs, increasing aging population and increase in health insurance policies. The key challenges include price regulation in the insulin market, competition from use of complementary and alternative medicines and maintainence of a healthy lifestyle to avoid diabetes.

The government initiatives section gives a brief description of the different diabetes programmes undertaken by the Government.

A brief overview of the drug regulations and patents is presented in the next section. It focuses the different stages of clinical trial that a drug must pass through. Drug regulations in India and drugs approved for marketing have been provided. The section also provides a list of important patent approvals for anti-diabetic drugs.

The competition section gives overview of pharmaceutical companies in the country operating in the anti diabetic pharmaceutical and insulin segments along with segmentation of players in respect to production of oral drugs and insulin. Thereafter, the report highlights the features of the major players operating in the market in detail. It includes elaborate profile of the major players in the market along with their financial analysis. Porters Five Forces Analysis has been incorporated for a brief but effective understanding of the market scenario.

The strategic recommendations section focuses on some effective strategic decisions which can be taken up by companies to increase their market shares.


Page 1: Executive summary

    Introduction

      Page 2: Types of diabetes

        Page 3: Classification of the diabetes market

          Page 4: Classes of anti-diabetic drugs

            Market Overview

              Page 5: Global Anti-Diabetic Pharmaceuticals Market - Overview, Size & Growth (Value: 2010-15e),

                Page 6: Indian Anti-Diabetic Pharmaceuticals Market - Overview, Size & Growth (Value: 2010-2015e), Growth in Therapeutic segments

                  Page 7: Global Diabetes map

                    Drivers & Challenges

                      Page 8: Summary

                        Page 9-12: Drivers

                          Page13-14: Challenges

                            Government initiatives

                              Page 15: Government programmes

                                Market Value Chain, Regulation and Patents

                                  Page 16: Pharmaceutical value chain

                                    Page17: Phases of clinical trials

                                      Page18-19: Drug regulations

                                        Page 20: Regulatory framework

                                          Page 21: List of patent approvals

                                            Competition

                                              Page 22: Competition overview

                                                Page 23: Segmentation of players

                                                  Page 24: Market Competition - Porter'sFive Forces Analysis

                                                    Page 25: Summary- Major public players

                                                      Page 26-61: Major Public Players

                                                        Aventis Pharma Limited

                                                          Biocon Limited

                                                            Cipla Limited

                                                              Dr. Reddy's Laboratories Limited

                                                                GlaxoSmithKline Pharmaceuticals Limited

                                                                  Merck Limited

                                                                    Panacea Biotec Limited

                                                                      Ranbaxy Laboratories Limited

                                                                        Strides Arcolab Limited

                                                                          Sun Pharmaceutical Industries Limited

                                                                            Torrent Pharmaceuticals Limited

                                                                              Wockhardt Limited

                                                                                Page 62: Summary - Major Private Players

                                                                                  Page 63-74: Major Private Players

                                                                                    Bristol-Myers Squibb India Private Limited

                                                                                      Eli Lilly and Company (India) Private Limited

                                                                                        Novo Nordisk India Private Limited

                                                                                          Takeda Pharmaceuticals India Private Limited

                                                                                            Page 75: Recent Developments

                                                                                              Strategic Recommendation

                                                                                                Page 76: Strategic Recommendations

                                                                                                  List of Charts & Figures

                                                                                                    Market Overview

                                                                                                      1. Anti Diabetic Pharmaceutical Market- Global Market Size and Growth (Value wise 2010 - 2015e)

                                                                                                        2. Market Segmentation- Global (Percentage wise 2010 & 2015e)

                                                                                                          3. Anti Diabetic Pharmaceutical Market - India Market Size and Growth (Value-Wise, 2010 - 2015e)

                                                                                                            4. Growth in therapeutic segments (Percentage wise 2010)

                                                                                                              5. Market Segmentation- India (Percentage wise 2010 & 2015e)

                                                                                                                Drivers and Challenges

                                                                                                                  6. Increase in diabetic patients - India (Value wise 2010 - 2030e)

                                                                                                                    7. Demography- People >60 years in India (Value- Wise 2005 - 2020e)

                                                                                                                      Competition

                                                                                                                        8. Bubble chart: Competitive summary of major public and private companies

                                                                                                                          Except Takeda Pharmaceuticals India Private Limited

                                                                                                                            9. Financial Snapshot

                                                                                                                              10. Key Business segments (only Public Players)

                                                                                                                                11. Key Geographic segments (only Public Players)

                                                                                                                                  Except GlaxoSmithKline Pharmaceuticals Limited

                                                                                                                                    List of Tables

                                                                                                                                      Market Value Chain, Regulation and Patent

                                                                                                                                        1. Tabular representation of drugs approved in recent past (2008- 2010)

                                                                                                                                          2. Tabular representation of regulatory framework of Indian Pharmaceutical Industry

                                                                                                                                            3. Tabular representation of USFDA patent approvals

                                                                                                                                              Competition

                                                                                                                                                4. Segmentation of pharmaceutical companies

                                                                                                                                                  5. Company profiles (All companies)

                                                                                                                                                    a. Company information

                                                                                                                                                      b. Products and services

                                                                                                                                                        c. Key people

                                                                                                                                                          d. Key Financial Performance Indicators

                                                                                                                                                            e. Key Ratios

                                                                                                                                                              f. Business Highlights

                                                                                                                                                                Appendix

                                                                                                                                                                  6. Ratio Calculations

                                                                                                                                                                  Summary:
                                                                                                                                                                  Get latest Market Research Reports on Anti-Diabetic Pharmaceuticals . Industry analysis & Market Report on Anti-Diabetic Pharmaceuticals is a syndicated market report, published as Anti-Diabetic Pharmaceuticals Market in India 2012. It is complete Research Study and Industry Analysis of Anti-Diabetic Pharmaceuticals market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

                                                                                                                                                                  Last updated on

                                                                                                                                                                  REPORT YOU MIGHT BE INTERESTED

                                                                                                                                                                  Purchase this Report

                                                                                                                                                                  $950.00
                                                                                                                                                                  $950.00
                                                                                                                                                                  757.15
                                                                                                                                                                  757.15
                                                                                                                                                                  882.55
                                                                                                                                                                  882.55
                                                                                                                                                                  145,568.50
                                                                                                                                                                  145,568.50
                                                                                                                                                                  79,268.00
                                                                                                                                                                  79,268.00
                                                                                                                                                                  Credit card Logo

                                                                                                                                                                  Related Reports


                                                                                                                                                                  Reason to Buy

                                                                                                                                                                  Request for Sample of this report